A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2013
11/28/2013	US20130317006 Use of polymorphisms for identifying individuals at risk of developing autism
11/28/2013	US20130317005 Non-hygroscopic salts of 5-ht2c agonists
11/28/2013	US20130317004 Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
11/28/2013	US20130317002 Fused pyrimidines
11/28/2013	US20130316999 Substituted oxazolidinones and their use in the field of blood coagulation
11/28/2013	US20130316998 Method for treating pancreatic cancer
11/28/2013	US20130316996 Transdermal delivery rate control using amorphous pharmaceutical compositions
11/28/2013	US20130316994 Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
11/28/2013	US20130316991 Biologically active supplements and process of its production
11/28/2013	US20130316990 Use of vitamin d compounds
11/28/2013	US20130316989 Compositions and methods for the treatment of inflammatory disease
11/28/2013	US20130316988 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases
11/28/2013	US20130316987 Anti-Thrombotic Compounds
11/28/2013	US20130316986 Anti-Thrombotic Compounds
11/28/2013	US20130316985 GPR35 Ligands And Uses Thereof
11/28/2013	US20130316983 Drug screening method, compositions and methods of treating glaucoma
11/28/2013	US20130316981 Tertiary amines, medicaments containing said amines, use thereof and processes for the preparation thereof
11/28/2013	US20130316980 Hypotonic Aqueous Composition with Reduced Chloride Content, With or Without Phospholipids
11/28/2013	US20130316978 Boronic acid derivatives and therapeutic uses thereof
11/28/2013	US20130316977 Priming solutions for cardiopulmonary bypass
11/28/2013	US20130316976 Pharmaceutical preparation
11/28/2013	US20130316974 Oxidized regenerated cellulose hemostatic powders and methods of making
11/28/2013	US20130316972 Prebiotic Formulations and Methods of Use
11/28/2013	US20130316971 Use of trehalose for prevention of neural tube defects
11/28/2013	US20130316969 Antiviral phosphonate analogs
11/28/2013	US20130316968 Maintenance of Platelet Inhibition During Antiplatelet Therapy
11/28/2013	US20130316967 Compounds and methods for enhancing erythropoiesis
11/28/2013	US20130316966 Use of albiflorin and metabolites thereof
11/28/2013	US20130316965 Idrabiotaparinux for the treatment of pulmonary embolism and for the secondary prevention of venous thromboembolic events
11/28/2013	US20130316961 Treatment of mecp-2 associated disorders
11/28/2013	US20130316953 New uses for amino acid anticonvulsants
11/28/2013	US20130316032 Substance for preventing and improving arthritis
11/28/2013	US20130316029 Methods and compositions suitable for managing blood glucose in animals
11/28/2013	US20130316026 Xylitol-based anti-mucosal compositions and related methods and compositions
11/28/2013	US20130316021 Treatment of respiratory diseases
11/28/2013	US20130316017 Oral Composition for the Treatment of Acne
11/28/2013	US20130316016 Antibacterial or anti-acne formulations containing usnic acid or an usnate and a metal salt
11/28/2013	US20130316010 Polymeric microparticles
11/28/2013	US20130316005 Combination and composition for treating obesity
11/28/2013	US20130316003 Controlled release pharmaceutical compositions comprising a fumaric acid ester
11/28/2013	US20130316001 Particles, compositions and methods for ophthalmic and/or other applications
11/28/2013	US20130316000 Compositions and methods for treatment of irritable bowel syndrome with 5-aminosalicylate
11/28/2013	US20130315998 Topical Foam Composition
11/28/2013	US20130315995 Direct compression polymer tablet core
11/28/2013	US20130315994 Modified-release dosage forms of 5-ht2c agonists useful for weight management
11/28/2013	US20130315993 Controlled release pharmaceutical compositions comprising a fumaric acid ester
11/28/2013	US20130315990 Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
11/28/2013	US20130315988 Pharmaceutical Composition
11/28/2013	US20130315986 Tumor-Specific Delivery of Therapeutic Agents Via Liposomase
11/28/2013	US20130315984 Anti-trypanosomal peptides and uses thereof
11/28/2013	US20130315983 Methods and compositions for the treatment of cancer
11/28/2013	US20130315982 Liposomal drug composition containing a polymeric guanidine derivative
11/28/2013	US20130315981 Method for inducing fat loss in mammals
11/28/2013	US20130315979 Glucan Gels
11/28/2013	US20130315978 Patch and patch preparation
11/28/2013	US20130315977 Transdermal patch
11/28/2013	US20130315975 Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
11/28/2013	US20130315974 Non-Hormonal Female Contraceptive
11/28/2013	US20130315968 Omega-3 diglyceride emulsions
11/28/2013	US20130315965 Harmine derivatives for promoting bone growth
11/28/2013	US20130315962 Method for stem cell differentiation in vivo by delivery of morphogenes with mesoporous silica and corresponding pharmceutical active ingredients
11/28/2013	US20130315938 Delivering polypeptides to phagocytes
11/28/2013	US20130315937 Lipid nanoparticle compositions for antisense oligonucleotides delivery
11/28/2013	US20130315932 Methods and pharmaceutical compositions for the treatment of heart failure
11/28/2013	US20130315926 Methods and materials for modulating resistance to apoptosis
11/28/2013	US20130315925 Method for treating and preventing type 2 diabetes
11/28/2013	US20130315903 Arylsulfonamide derivatives for the prevention or treatment of specific ophthalmologic disorders
11/28/2013	US20130315899 Methods and compositions for diagnostic use in cancer patients
11/28/2013	US20130315897 Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor
11/28/2013	US20130315895 COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
11/28/2013	US20130315883 Control of pathogens and parasites
11/28/2013	US20130315868 D-amino acid compounds for liver disease
11/28/2013	US20130315867 3',5'-cyclic phosphate prodrugs for hcv infection
11/28/2013	US20130315866 3',5'-cyclic phosphoramidate prodrugs for hcv infection
11/28/2013	US20130315865 Triazine compounds as pi3 kinase and mtor inhibitors
11/28/2013	US20130315864 Macrocyclic nucleoside phosphoramidate derivatives
11/28/2013	US20130315863 Methods and compositions for treating flaviviridae infections
11/28/2013	US20130315862 Methods and compositions for treating hepatitis c virus
11/28/2013	US20130315861 Inhibitors of flaviviridae viruses
11/28/2013	US20130315844 Oral Care Compositions
11/28/2013	US20130315831 Lipid-polymer hybrid particles
11/28/2013	DE102012208530A1 Substituierte Piperidinoacetamide und ihre Verwendung Substituted Piperidinoacetamide and their use
11/28/2013	DE102012104451A1 Komposition zur Behandlung einer Störung des circadianen Rhythmus Composition for treating a disorder of circadian rhythm
11/28/2013	CA2875990A1 Heterocyclyl pyrimidine analogues as tyk2 inhibitors
11/27/2013	EP2667186A1 Fine structure determination method of enoxaparin sodium based on capillary electrophoresis
11/27/2013	EP2666859A2 Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
11/27/2013	EP2666858A1 Modified iRNA agents
11/27/2013	EP2666856A1 Composition for inhibiting target gene expression
11/27/2013	EP2666788A1 Glucan fibre
11/27/2013	EP2666777A1 Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods
11/27/2013	EP2666776A1 Pyrazolopyrimidinone compound and imidazo-triazone compound for treating erectile dysfunction
11/27/2013	EP2666775A1 Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
11/27/2013	EP2666774A1 Beta-lactamase Inhibitors
11/27/2013	EP2666773A1 Organic amine salts of azilsartan, preparation method and use thereof
11/27/2013	EP2666769A1 Substituted B-amino acid derivatives as CXCR3 receptor antagonist
11/27/2013	EP2666767A1 Therapeutic agent for TRPV1-mediated disease
11/27/2013	EP2666766A1 Novel E,E-diene compounds and their use as medicaments and cosmetics
11/27/2013	EP2666764A1 Ferric citrate containing substantially no -oxidized iron hydroxide
11/27/2013	EP2666761A1 Hydroxytyrosol ethers
11/27/2013	EP2666482A1 Particle composition and pharmaceutical composition using particle composition

1 ... 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 ... 7860